Specification
| Target | LILRA4 |
| Reactivities | Human |
| Biosimilar | Daxbio |
| Isotype | Human IgG1(K214R)-Lambda2(K83R） |
| Property | Antibody |
| Alternative | CD85 antigen-like family member G; CD85g antigen; CD85g; ILT7; ILT-7; ILT7MGC129598; Immunoglobulin-like transcript 7; leukocyte immunoglobulin-like receptor subfamily A member 4; leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 4; leukocyte immunoglobulin-like receptor, subfamily A (without TM domain), member4; LILRA4; |
| Recommend Isotype | |
| Formulation Buffer | PBS, pH 7.4,Contains no stabilizers or preservatives |
| Recommend Buffer | PBS, pH 7.4,Contains no stabilizers or preservatives. |
| Endotoxin | <1EU/mg Determined by LAL gel clotting assay |
| Purity | >95% Determined by SDS-PAGE |
| Sterility | 0.2 μM filtered |
| Expression Host | CHO |
| Purification method | Protein A |
| Storage | The product should be stored at the original stock concentration at 4°C. Avoid freeze-thaw cycles. |
| Note | Due to the variability in applications, investigators should consult application references to estimate the appropriate dose or concentration. This dose or concentration can then be further optimized through experimental methods such as dose-response or titration experimentsThe sequence of this product comes from:IMGT |
Background
QC Data
| Note | Please contact us for QC Data |
| Product Image (Reference Only) |  |